A number of synthetically lethal therapeutic opportunities arise on the basis of ARID1A mutations and mismatch repair deficiency, utilizing inhibitors of PARP1, HDAC2/6, Aurora kinase A, CKD4/6, or PI3K/Akt [50]. The gene discussed is AKT1; the disease is mismatch repair cancer syndrome 1.